{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:03:41Z","timestamp":1790960621671,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231039"],"award-info":[{"award-number":["K20231039"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231049"],"award-info":[{"award-number":["K20231049"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104244"],"award-info":[{"award-number":["82104244"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jad.2025.01.022","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:56:20Z","timestamp":1736362580000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data"],"prefix":"10.1016","volume":"374","author":[{"given":"Zhaohui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.01.022_bb0005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","article-title":"Review on Alzheimer\u2019s disease: inhibition of amyloid beta and tau tangle formation[J]","volume":"167","author":"Ashrafian","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jad.2025.01.022_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2025.01.022_bb0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.jad.2025.01.022_bb0020","doi-asserted-by":"crossref","first-page":"e1534","DOI":"10.1016\/S2214-109X(24)00264-X","article-title":"The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories[J]","volume":"12","author":"Chen","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jad.2025.01.022_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer\u2019s disease: a systematic review[J]","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.01.022_bb0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease[J]","volume":"10","author":"Cohen","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.jad.2025.01.022_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"issue":"6","key":"10.1016\/j.jad.2025.01.022_bb0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.01.022_bb0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database[J]","volume":"362","author":"Gu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0050","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease[J]","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/j.jad.2025.01.022_bb0055","first-page":"1","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database[J]","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0060","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0065","doi-asserted-by":"crossref","first-page":"17138","DOI":"10.1038\/s41598-024-67627-0","article-title":"Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of Vilazodone: evidence from the FAERS database[J]","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.01.022_bb0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database[J]","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.01.022_bb0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.14283\/jpad.2023.122","article-title":"Alzheimer\u2019s disease-associated APOE \u03b54 frequencies in Indian population genomes may suggest implications in Lecanemab treatment[J]","volume":"11","author":"Jolly","year":"2024","journal-title":"J. Prev Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.14283\/jpad.2023.61","article-title":"Burden of illness in people with Alzheimer\u2019s disease: a systematic review of epidemiology, comorbidities and mortality[J]","volume":"11","author":"Lanct\u00f4t","year":"2024","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.jad.2025.01.022_bb0090","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database[J]","volume":"354","author":"Lu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2025.01.022_bb0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0100","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease[J]","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jad.2025.01.022_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113320","article-title":"Alzheimer\u2019s disease and its treatment by different approaches: a review[J]","volume":"216","author":"Srivastava","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease[J]","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jad.2025.01.022_bb0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies[J]","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jad.2025.01.022_bb0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database[J]","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272500028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272500028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:44:06Z","timestamp":1777337046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272500028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"alternative-id":["S016503272500028X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.01.022","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}